JOINN adheres to the purpose of "Serve for Drug Innovation,
Focus on Safety Assessments and Monitoring of Drugs Throughout Life Cycles"

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024 (REVISED)

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024 (REVISED)

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2024

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2024

CONTINUING CONNECTED TRANSACTIONS: (1) 2024 BEIJING JOINN BIOLOGICS LEASING FRAMEWORK AGREEMENT; AND (2) BIOAI SERVICE FRAMEWORK AGREEMENT

CONTINUING CONNECTED TRANSACTIONS: (1) 2024 BEIJING JOINN BIOLOGICS LEASING FRAMEWORK AGREEMENT; AND (2) BIOAI SERVICE FRAMEWORK AGREEMENT

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024

REPURCHASE AND CANCELLATION OF THE RESTRICTED A SHARES

REPURCHASE AND CANCELLATION OF THE RESTRICTED A SHARES

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024

Final dividend in cash for the year ended December 31, 2023

Final dividend in cash for the year ended December 31, 2023

Leave us a message

Thank you for your attention to JOINN. Please fill in the information below, and we will contact you promptly.

Message

Message

top